EGFR and endometrial cancer: Therefore, combined therapy that includes targeting of NMU signaling may enhance the efficacy of current drugs that are designed to inhibit EGFR and/or TGFβ receptor pathways; such an approach could be beneficial when treating patients with aggressive endometrial cancer.